Post-traumatic stress affects cognitive function in cancer patients

May 4, 2017
Post-traumatic stress affects cognitive function in cancer patients
Credit: lightpoet / fotolia.com

Subtle cognitive dysfunction and decline in breast cancer patients was largely independent of chemotherapy but associated with cancer-related post-traumatic stress in a German multisite study.

Many report problems of , and some are considerably burdened by them. These symptoms have mainly been attributed to neurotoxic effects of chemotherapy, as reflected in the colloquial term 'chemobrain'. Now a longitudinal study in newly diagnosed cancer patients from six institutions in the area of Munich, Germany, investigated the role of post-traumatic in the causation of cancer-related cognitive impairment. The project was funded by the Deutsche Krebshilfe and led by psychologist Kerstin Hermelink (Department of Gynecology and Obstetrics, CCC LMU University Hospital of Munich). In the first year after diagnosis, breast cancer patients treated with and without chemotherapy showed minimal and decline, which were associated with post-traumatic stress due to having cancer. "It is well-established that post-traumatic stress – not to be confused with everyday stresses – has disruptive effects on the brain," Hermelink says. "For many patients, being diagnosed with breast cancer is a traumatic experience. The hypothesis that cognitive dysfunction in breast cancer patients is caused by post-traumatic stress seemed therefore worth pursuing."

One-hundred sixty-six newly diagnosed breast cancer patients and 60 women who had undergone routine breast imaging with negative results participated in the Cognicares (Cognition in Breast Cancer Patients: The Impact of Cancer-Related Stress) study. In all participants, post-traumatic symptoms were assessed with a clinical interview, and cognitive function was evaluated with a battery of paper-and-pencil and computer-based neuropsychological tests three times over the course of one year.

In comparison with the control group, the patients showed minimal overall cognitive decline and demonstrated less accuracy on one of several tests of attention before the start of treatment and one year later. All these deficits were associated with symptoms of (PTSD), and the effect of having breast cancer on attention lost statistical significance if the effect of post-traumatic stress was taken into account. In contrast, only patients who had received chemotherapy showed longer reaction times than other participants on a test of alertness at one year. The test required pressing a mouse button whenever a cross appeared on a monitor, and the results were unrelated to PTSD symptoms. "The difference in performance was minimal – 19 milliseconds, on average – and it may at least partly be due to peripheral neuropathy, damage to the nerves of the fingers caused by certain cytostatic agents," Hermelink explains.

The findings of the Cognicares study suggest that psychological factors may contribute more importantly to cancer-related cognitive impairment than of treatment. "The brain is not a computer that delivers the same level of performance no matter what. Its function and structure are in constant flux, as it reacts and adapts to our experiences and actions," Hermelink points out. "Indeed, it would be surprising if the psychological consequences and the life disruption brought about by having cancer were not impacting he brain and its functioning. Our study focused on the effects of post-traumatic stress. Further factors like insomnia, anxiety and depression, all of which are highly prevalent in breast cancer patients, and lack of cognitive training caused by prolonged sick leave may also affect cognitive function. The role of psychological factors, however, has rarely been investigated. In virtually all studies, they were only assessed with self-report screening questionnaires. Given the small effects we are concerned with, these measures are not precise enough." The Cognicares study provides some reassurance for breast . Subtle cognitive impairment they may experience does not seem to be an inevitable neurotoxic side-effect of chemotherapy but a consequence of post-traumatic stress and possibly further treatable and modifiable factors.

Explore further: Cancer-related PTS linked to very limited cognitive impairment among newly diagnosed breast cancer patients

More information: Kerstin Hermelink et al. Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients, JNCI: Journal of the National Cancer Institute (2017). doi.org/10.1093/jnci/djx057

Related Stories

Cancer-related PTS linked to very limited cognitive impairment among newly diagnosed breast cancer patients

April 16, 2015
Cancer-related post-traumatic stress is associated with very limited cognitive impairment before treatment among newly diagnosed breast cancer patients, according to a new study published April 16 in the JNCI: Journal of ...

The mental trauma of severe breast cancer

March 2, 2016
According to a study led by Ludwig-Maximilians-Universitaet (LMU) in Munich researchers, a majority of patients diagnosed with breast cancer go on to develop symptoms of post-traumatic stress disorder, and in most of these ...

Chemo-brain among women with breast cancer is pervasive, study shows

December 29, 2016
The largest study to date of a condition known as "chemo-brain" shows that women with breast cancer report it's a substantial problem after chemotherapy for as long as six months after treatment, according to investigators ...

Neurotoxic effects of chemotherapies on cognition in breast cancer survivors

December 3, 2015
Cancer-related cognitive impairment is often referred to as 'chemobrain' and anthracycline-based chemotherapy may have greater negative effects on particular cognitive domains and brain network connections than nonanthracycline-based ...

Online program reduces neurological symptoms linked to chemotherapy in cancer patients

October 31, 2016
Up to 70 per cent of cancer patients report cognitive symptoms following chemotherapy. These symptoms have been linked to poorer quality of life and increased depression, anxiety, and fatigue among cancer survivors.

Many partners of young breast cancer patients suffer anxiety

January 25, 2017
(HealthDay)—Breast cancer can take a heavy toll on the partners of patients, too, according to a study presented at the American Society of Clinical Oncology's Cancer Survivorship Symposium, held from Jan. 27 to 28 in San ...

Recommended for you

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.